Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.

Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH.

J Clin Oncol. 2013 Feb 10;31(5):592-8. doi: 10.1200/JCO.2012.44.5791. Epub 2013 Jan 7.

PMID:
23295809
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.

Br J Cancer. 1999 Oct;81(3):476-83.

PMID:
10507773
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.

J Clin Oncol. 2003 Feb 15;21(4):607-14.

PMID:
12586796
[PubMed - indexed for MEDLINE]
4.

Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.

Delwail V, Jais JP, Colonna P, Andrieu JM.

Br J Haematol. 2002 Jul;118(1):189-94.

PMID:
12100147
[PubMed - indexed for MEDLINE]
5.

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A.

Blood. 2014 Mar 13;123(11):1658-64. doi: 10.1182/blood-2013-07-512657. Epub 2014 Jan 29.

PMID:
24478403
[PubMed - indexed for MEDLINE]
6.

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.

Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group.

J Clin Oncol. 2003 Sep 15;21(18):3440-6. Epub 2003 Mar 7.

PMID:
12668650
[PubMed - indexed for MEDLINE]
7.

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.

Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.

Haematologica. 1998 Sep;83(9):812-23.

PMID:
9825578
[PubMed - indexed for MEDLINE]
Free Article
8.

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi.

J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19.

PMID:
16172458
[PubMed - indexed for MEDLINE]
Free Article
9.

Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.

Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G.

Cancer Treat Rep. 1986 Mar;70(3):343-8.

PMID:
2420444
[PubMed - indexed for MEDLINE]
10.

[Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].

Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):630-4. Chinese.

PMID:
19102946
[PubMed - indexed for MEDLINE]
11.

Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.

Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G, Gadner H.

J Clin Oncol. 1997 Jun;15(6):2247-53.

PMID:
9196137
[PubMed - indexed for MEDLINE]
12.

Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.

Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD.

Am J Clin Oncol. 2004 Feb;27(1):73-80.

PMID:
14758137
[PubMed - indexed for MEDLINE]
13.

Hodgkin's disease and the risk of acute leukemia in successfully treated patients.

Valagussa P, Bonadonna G.

Haematologica. 1998 Sep;83(9):769-70. No abstract available.

PMID:
9825571
[PubMed - indexed for MEDLINE]
Free Article
14.

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.

Cancer. 2000 May 1;88(9):2142-8.

PMID:
10813727
[PubMed - indexed for MEDLINE]
15.

Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.

Zinzani PL, Fiacchini M, Mazza P, Gherlinzoni F, Bocchia M, Tura S.

Haematologica. 1991 Jul-Aug;76(4):305-10.

PMID:
1724437
[PubMed - indexed for MEDLINE]
16.

[Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].

Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.

Sangre (Barc). 1998 Jun;43(3):179-84. Review. Spanish.

PMID:
9741222
[PubMed - indexed for MEDLINE]
17.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ.

Br J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29.

PMID:
23356491
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.

Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.

Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):765-81.

PMID:
15183480
[PubMed - indexed for MEDLINE]
19.

Second cancer among long-term survivors from Hodgkin's disease.

Nyandoto P, Muhonen T, Joensuu H.

Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):373-8.

PMID:
9788418
[PubMed - indexed for MEDLINE]
20.

Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.

Hamilton VM, Norris C, Bunin N, Goldwein JW, Bunin GR, Lange B, Meadows AT.

J Pediatr Hematol Oncol. 2001 Feb;23(2):84-8.

PMID:
11216711
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk